Chemotherapy-Induced Thrombosis: A Role for Microparticles and Tissue Factor?

 

 Buy Article Permissions and Reprints

ABSTRACT

Chemotherapy is an independent risk factor of thromboembolic events in cancer patients. Various pathogenetic mechanisms have been hypothesized in the past, but until now their individual contribution to the risk of thrombosis has been hardly investigated in clinical trials. In recent years, studies increasingly suggested an association between the prothrombotic state in cancer patients and circulating tissue factor–exposing microparticles. In this review, we discuss the roles of tissue factor and microparticles with regard to chemotherapy-induced hypercoagulability.

REFERENCES

• 1 Otten H M, Mathijssen J, ten Cate H et al.. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.  Arch Intern Med. 2004;  164 190-194
  CrossrefPubMedGoogle Scholar
• 2 Sallah S, Wan J Y, Nguyen N P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics.  Thromb Haemost. 2002;  87 575-579
  PubMedGoogle Scholar
• 3 Khorana A A, Francis C W, Culakova E, Kuderer N M, Lyman G H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.  J Thromb Haemost. 2007;  5 632-634
  CrossrefPubMedGoogle Scholar
• 4 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.  Thromb Haemost. 1997;  78 133-136
  PubMedGoogle Scholar
• 5 Dhami M S, Bona R D, Calogero J A, Hellman R M. Venous thromboembolism and high grade gliomas.  Thromb Haemost. 1993;  70 393-396
  PubMedGoogle Scholar
• 6 Numico G, Garrone O, Dongiovanni V et al.. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.  Cancer. 2005;  103 994-999
  CrossrefPubMedGoogle Scholar
• 7 Khorana A A, Francis C W, Culakova E, Lyman G H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.  Cancer. 2005;  104 2822-2829
  CrossrefPubMedGoogle Scholar
• 8 Levine M N, Gent M, Hirsh J et al.. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.  N Engl J Med. 1988;  318 404-407
  CrossrefPubMedGoogle Scholar
• 9 Khorana A A, Kuderer N M, Culakova E, Lyman G H, Francis C W. Development and validation of a predictive model for chemotherapy-associated thrombosis.  Blood. 2008;  111 4902-4907
  CrossrefPubMedGoogle Scholar
• 10 Lyman G H, Khorana A A, Falanga A et al.. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.  J Clin Oncol. 2007;  25 5490-5505
  CrossrefPubMedGoogle Scholar
• 11 Paredes N, Xu L, Berry L R, Chan A K. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces.  Br J Haematol. 2003;  120 315-324
  CrossrefPubMedGoogle Scholar
• 12 Aitokallio-Tallberg A, Viinikka L, Ylikorkala O. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment.  Br J Cancer. 1989;  60 785-788
  PubMedGoogle Scholar
• 13 Walsh J, Wheeler H R, Geczy C L. Modulation of tissue factor on human monocytes by cisplatin and adriamycin.  Br J Haematol. 1992;  81 480-488
  PubMedGoogle Scholar
• 14 Togna G I, Togna A R, Franconi M, Caprino L. Cisplatin triggers platelet activation.  Thromb Res. 2000;  99 503-509
  CrossrefPubMedGoogle Scholar
• 15 Bertomeu M C, Gallo S, Lauri D, Levine M N, Orr F W, Buchanan M R. Chemotherapy enhances endothelial cell reactivity to platelets.  Clin Exp Metastasis. 1990;  8 511-518
  CrossrefPubMedGoogle Scholar
• 16 Woodley-Cook J, Shin L Y, Swystun L, Caruso S, Beaudin S, Liaw P C. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway.  Mol Cancer Ther. 2006;  5 3303-3311
  CrossrefPubMedGoogle Scholar
• 17 Feffer S E, Carmosino L S, Fox R L. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil.  Cancer. 1989;  63 1303-1307
  CrossrefPubMedGoogle Scholar
• 18 Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.  Cancer. 1990;  65 885-889
  CrossrefPubMedGoogle Scholar
• 19 Liebman H A, Wada J K, Patch M J, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase.  Cancer. 1982;  50 451-456
  CrossrefPubMedGoogle Scholar
• 20 Mewhort-Buist T A, Liaw P C, Patel S, Atkinson H M, Berry L R, Chan A K. Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma.  Thromb Res. 2008;  , in press
  PubMedGoogle Scholar
• 21 Oner A F, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase.  Leuk Lymphoma. 1999;  33 361-364
  PubMedGoogle Scholar
• 22 Lopez J A, Kearon C, Lee A Y. Deep venous thrombosis.  Hematology (Am Soc Hematol Educ Program). 2004;  1 439-456
  PubMedGoogle Scholar
• 23 Falati S, Gross P, Merrill-Skoloff G, Furie B C, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse.  Nat Med. 2002;  8 1175-1181
  CrossrefPubMedGoogle Scholar
• 24 Giesen P L, Rauch U, Bohrmann B et al.. Blood-borne tissue factor: another view of thrombosis.  Proc Natl Acad Sci U S A. 1999;  96 2311-2315
  Google Scholar
• 25 Sturk-Maquelin K N, Nieuwland R, Romijn F P, Eijsman L, Hack C E, Sturk A. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo.  J Thromb Haemost. 2003;  1 1920-1926
  CrossrefPubMedGoogle Scholar
• 26 Yu J L, Rak J W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells.  J Thromb Haemost. 2004;  2 2065-2067
  Google Scholar
• 27 Freyssinet J M. Cellular microparticles: what are they bad or good for?.  J Thromb Haemost. 2003;  1 1655-1662
  CrossrefPubMedGoogle Scholar
• 28 Hron G, Kollars M, Weber H et al.. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.  Thromb Haemost. 2007;  97 119-123
  Google Scholar
• 29 Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5 520-527
  CrossrefPubMedGoogle Scholar
• 30 Zwicker J I, Kos C A, Johnston K A, Liebman H A, Furie B C, Furie B. Cancer-associated thrombosis: tissue factor-bearing microparticles are associated with an increased risk of venous thromboembolic events in cancer patients.  J Thromb Haemost. 2007;  5 , (abstract O-M-005)
  PubMedGoogle Scholar
• 31 Licciardello J T, Moake J L, Rudy C K, Karp D D, Hong W K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy.  Oncology. 1985;  42 296-300
  PubMedGoogle Scholar
• 32 Lechner D, Kollars M, Gleiss A, Kyrle P A, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity.  J Thromb Haemost. 2007;  5 2445-2452
  CrossrefPubMedGoogle Scholar
• 33 Weber H, Lechner D, Kollars M, Eichinger S, Kyrle P A, Weltermann A. Shedding of procoagulant microparticles from tumor cells after chemotherapy.  Hämostaseologie. 2007;  01 , (abstract FV05)
  PubMedGoogle Scholar
• 34 Kim H K, Song K S, Park Y S, Kim C M, Lee K R. Method comparison of flow cytometric assay of platelet microparticles and changes of platelet microparticles during cancer chemotherapy.  Thromb Haemost. 2002;  87 547-548
  PubMedGoogle Scholar
• 35 Periard D, Boulanger C M, Eyer S et al.. Are circulating endothelial-derived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke?.  Stroke. 2007;  38 1636-1638
  CrossrefPubMedGoogle Scholar
• 36 Simak J, Holada K, Vostal J G. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin.  BMC Cell Biol. 2002;  3 11
  CrossrefPubMedGoogle Scholar
• 37 Telgenhoff D J, Aggarwal S K, Johnson B N. Histochemical and morphological identification of Kupffer cells activated by cisplatin.  Anticancer Res. 1999;  19 1005-1010
  PubMedGoogle Scholar
• 38 Willekens F L, Werre J M, Kruijt J K et al.. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors.  Blood. 2005;  105 2141-2145
  CrossrefPubMedGoogle Scholar
• 39 Falati S, Liu Q, Gross P et al.. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.  J Exp Med. 2003;  197 1585-1598
  CrossrefPubMedGoogle Scholar
• 40 Levitan N, Dowlati A, Remick S C et al.. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.  Medicine (Baltimore). 1999;  78 285-291
  CrossrefPubMedGoogle Scholar

Ansgar WeltermannM.D. 

Department of Medicine I, Medical University of Vienna

Waehringer Guertel 18-20, A-1090 Vienna, Austria

Email: ansgar.weltermann@meduniwien.ac.at